Atara Biotherapeutics Inc. (NASDAQ:ATRA) – Investment analysts at William Blair lifted their FY2019 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a report released on Monday. William Blair analyst J. Sonnier now anticipates that the firm will post earnings per share of ($3.20) for the year, up from their previous estimate of ($3.21). William Blair also issued estimates for Atara Biotherapeutics’ FY2020 earnings at ($3.32) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.10.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Several other analysts have also commented on ATRA. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a report on Sunday, November 6th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Jefferies Group reissued a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, August 9th. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their target price for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Finally, Citigroup Inc. upped their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research report on Friday, August 19th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $25.86.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) remained flat at $19.45 during trading on Wednesday. 196,158 shares of the stock traded hands. The company has a 50-day moving average price of $16.69 and a 200 day moving average price of $19.65. The stock’s market capitalization is $561.33 million. Atara Biotherapeutics has a 12-month low of $12.45 and a 12-month high of $40.80.

Large investors have recently bought and sold shares of the stock. Barclays PLC boosted its stake in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the period. Panagora Asset Management Inc. acquired a new stake in Atara Biotherapeutics during the third quarter worth approximately $110,000. BlackRock Group LTD boosted its stake in Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock worth $119,000 after buying an additional 198 shares during the period. BlackRock Inc. boosted its stake in Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the period. Hedge funds and other institutional investors own 74.45% of the company’s stock.

In other news, CEO Isaac E. Ciechanover sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $20.87, for a total transaction of $250,440.00. Following the sale, the chief executive officer now directly owns 406,578 shares in the company, valued at approximately $8,485,282.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Gad Soffer sold 16,718 shares of the firm’s stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $20.00, for a total value of $334,360.00. Following the sale, the chief operating officer now owns 225,667 shares in the company, valued at $4,513,340. The disclosure for this sale can be found here. Company insiders own 16.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “FY2019 Earnings Forecast for Atara Biotherapeutics Inc. (ATRA) Issued By William Blair” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and reposted in violation of United States & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/24/fy2019-earnings-forecast-for-atara-biotherapeutics-inc-atra-issued-by-william-blair.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.